オプションチェーンは、Cannabix Technologiesの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Cannabix Technologiesの市場センチメントを評価します。.

Cannabix Technologies (OTC:BLOZF) 株価情報, オプションチェーン

Cannabix Technologies Inc development of the Cannabix marijuana breathalyzer. It is a developer of marijuana and alcohol breathalyzer technologies for law enforcement, workplaces, and laboratories. Its technology includes the THC Breathalyzer System, Breath Logix Alcohol Breathalyzer, and Breath Logix Vehicle.

CANNABIX TECHS INC ORD by Cannabix Technologies Inc.

Cannabix Technologies Inc

BMO Capital analyst Kostas Biliouris maintains Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Outperform and lowers the price target from $70 to $50.

News

Price Target

Analyst Ratings

NTLA

BMO Capital Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $50

BMO Capital analyst James Thalacker maintains American Electric Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) with a Outperform and lowers the price target from $108 to $100.

BMO Capital Maintains Outperform on American Electric Power, Lowers Price Target to $100

The December jobs report jolted financial markets during early Friday trading. Stronger-than-expected employment growth and a drop in the unemployment rate to 4.1% raised fears the Federal Reserve may hold off on cutting interest rates <a href="https://www.benzinga.com/news/econ-s">for most of 2025.</a>
<h3 class="wp-block-heading">December Jobs Report Fuels Fed Hawkishness: Dollar Soars, Yields Jump </h3>
The U.S. economy added 256,000 new jobs last month, marking an acceleration from the downwardly revised 212,000 jobs added in November and sharply outpacing economist forecasts of 160,000, as tracked by TradingEconomics.
The December reading represented the strongest monthly job growth since March 2024, underscoring the continued resilience of the U.S. economy despite high interest rates and resurgent inflationary pressures.
The unemployment rate ticked down from 4.2%to 4.1% in November, defying expectations of no change. Wages rose broadly in line with expectations, with average hourly earnings increasing 0.3% month-over-month, slowing slightly from November&#8217;s 0.4%. On a year-over-year basis, wages climbed 3.9%, marginally below the 4% forecast.
Fed fund futures showed a steep decline in the probability of a March rate cut, with implied odds dropping to just 26%, down from 43% a day earlier, according to CME&#8216;s FedWatch tool.
Treasury yields rose sharply across the curve, reflecting a repricing of interest rate expectations. 
The two-year yield, closely tied to Federal Reserve policy expectations, jumped 11 basis points to 4.37%. The 10-year yield surged 10 basis points to 4.79%, its highest level since November 2023.
Notably, the most striking move came in the 30-year yield, which breached the 5% mark for the first time since October 2023. Before that, the last time 30-year yields surpassed this milestone was in August 2007. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) dropped 1.2% in premarket trading, highlighting the market's sensitivity to long-term rates.
The U.S. Dollar Index, tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), surged 0.5% to 109.70, a level last seen in late October 2022. 
The greenback climbed 0.4% against the Japanese yen and 0.6% versus the euro, pushing the euro-dollar pair to a fresh 27-month low of 1.0250. The Sterling wasn&#8217;t spared, falling 0.7% to a 15-month low against the dollar.
<h3 class="wp-block-heading">Stocks Slump Across The Board</h3>
Futures on major U.S. indices were down 1% across the board, as the prospect of higher-for-longer interest rates rattled investors. All S&amp;P 500 sectors, except energy, traded in the negative premarket Friday.
Real estate, tracked by the Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>), and technology, represented by the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>), both sank 1.4%. 
Rate-sensitive sectors such as real estate and growth-heavy tech bore the brunt of the selloff as higher yields weighed on long-duration assets.
The one standout sector was energy, with the Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) climbing 1.3%.
<h3 class="wp-block-heading">Major Premarket Movers</h3>
Among energy giants, Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) gained 1.67% to $152.81, Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) rose 1.57% to $108.61 and ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) advanced 1.43% to $103.07, benefiting from a 3% spike in oil prices after Reuters reported thet U.S. is mulling stronger sanctions on Russia&#8217;s oil sector.
In contrast, rate-sensitive mega-cap tech stocks dragged the market lower. 
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) fell 2.51% to $136.59, Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) dropped 2.92% to $118.28 and American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) plunged 3.93% to $68.63, leading losses among financials.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/42901085/us-2025-recession-odds-plummet-good-news-or-warning-sign">US 2025 Recession Odds Plummet: Good News Or Warning Sign?</a></li>
</ul>
Photo via Shutterstock.

Equities

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Markets

ETFs

NVDA

iShares Trust Barclays 20+ Year Treasury Bond Fund

PowerShares DB US Dollar Index Bullish Fund

XLRE

Dollar Soars To 27-Month Highs, 30-Year Yields Hit 5%, Stocks Tumble As Jobs Report, Oil Spike Darken Fed's Interest Rate Cut Hopes

<ul>
<li>NVDA</li>
<li>AMD</li>
<li>TSLA</li>
<li>MVST</li>
<li>MSTR</li>
<li>RGTI</li>
<li>FUBO</li>
<li>QQQ</li>
<li>CVNA</li>
<li>RKLB</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

CVNA

FUBO

MSTR

MVST

RGTI

RKLB

TSLA

Top 10 Trending Stocks On WallStreetBets As Of January 10, 2025 (Via Swaggy Stocks)

RZLV

Shoeby To Use Rezolve Ai Technology

D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) on Friday said it expects significant booking growth<a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42908809/d-wave-announces-fiscal-year-2024-bookings-will-exceed-23-million-up-approximately-120-over-fiscal" rel="noreferrer noopener"> for fiscal year 2024.</a>
The company reported that its bookings will exceed $23 million, marking a 120% increase over fiscal year 2023.
The company&#8217;s CEO&nbsp;Alan Baratz has criticized&nbsp;Nvidia Corp. CEO&nbsp;Jensen Huang for his comments regarding the timeline for achieving practical quantum<a target="_blank" href="https://www.benzinga.com/25/01/42892470/jensen-huang-is-dead-wrong-about-quantum-computing-d-wave-ceo-fires-back-at-nvidia-boss-happy-to-meet-with-jensen-any-time-any-place-to-help-fill-in-these-gaps" rel="noreferrer noopener"> computing, saying he is &#8220;dead wrong.&#8221;</a>
Huang&#8217;s remarks during Nvidia&#8217;s analyst day, suggesting a 15 to 30-year wait for &#8220;very useful quantum computers,&#8221; have&nbsp;sparked a heated debate&nbsp;in the tech community.
A key driver of D-Wave&#8217;s growth is the first-ever customer purchase of the D-Wave Advantage system, a quantum computer with over 5,000 qubits.
This sale signals a major expansion of D-Wave&#8217;s revenue model, as it begins offering on-premise quantum systems in addition to its cloud services.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/01/42900817/quantum-stocks-regetti-computing-ionq-d-wave-poised-to-open-higher-after-nvidia-ceo-comments-drove-huge-losses" rel="noreferrer noopener">Quantum Stocks Regetti Computing, IonQ, D-Wave Poised To Open Higher After Nvidia CEO Comments Drove Huge Losses</a>
The Advantage system provides customers full access to its capabilities, allowing them to modify system parameters and integrate it into their own infrastructure.
D-Wave&#8217;s growing customer base, including research centers and businesses, highlights the increasing demand for quantum computing solutions, particularly for addressing challenges in AI power consumption and national security.
Additionally, D-Wave disclosed that its fiscal fourth-quarter 2024 bookings will reach at least $18 million, a staggering 500% increase over the same period last year.
The company also ended the fiscal year with a strong cash position of approximately $178 million.
Price Action: QBTS shares are trading higher by 0.66% to $6.14 premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/01/42908495/us-stocks-to-open-on-a-tentative-note-as-traders-remain-cautious-ahead-of-fridays-crucial-jobs-data" target="_blank" rel="noreferrer noopener">US Stocks To Open On A Tentative Note As Traders Remain Cautious Ahead Of Friday&#8217;s Crucial Jobs Data</a></li>
</ul>
Photo via Shutterstock.

Guidance

Movers

General

QBTS

What's Going On With D-Wave Quantum Stock Today?

Pennsylvania Sen. <a href="https://www.benzinga.com/topic/john-fetterman">John Fetterman</a> will become the first Democrat to join the slew of politicians and billionaire businesspeople who are making the trek to meet with President-elect Donald Trump at his Mar-a-Lago home <a href="https://www.benzinga.com/topic/mar-a-lago">in Palm Beach, Florida</a>.
Fetterman said in a statement Thursday that Trump invited him to meet and that he accepted.
"I'm the senator for all Pennsylvanians — not just Democrats in Pennsylvania," he said in a statement, <a href="https://www.cbsnews.com/news/fetterman-trump-mar-a-lago/" target="_blank" rel="noreferrer noopener">first</a> reported by CBS News. "I've been clear that no one is my gatekeeper. I will meet with and have a conversation with anyone if it helps me deliver for Pennsylvania and the nation."
The meeting is expected to take place this weekend.
The trip marks Fetterman's transition from a leading supporter of President Joe Biden into a "Trump-friendly lawmaker," as <a href="https://apnews.com/article/john-fetterman-donald-trump-maralago-d3bf4398cf71b7a66885f5b910dec9f6">described</a> by the Associated Press, following Trump&#8217;s victory in the battleground state of Pennsylvania.
<h2 class="wp-block-heading">From Bitter Enemies To Almost Friends</h2>
Fetterman <a href="https://www.benzinga.com/markets/cannabis/22/05/27268902/breaking-john-fetterman-wins-pennsylvania-democratic-senate-primary">was elected </a>to the Senate in 2022 in a knockdown battle against multimillionaire TV host Dr. Mehmet Oz, widely viewed as hand-picked by Trump. Things got nasty when Oz <a href="https://www.benzinga.com/markets/cannabis/22/08/28710156/dr-oz-campaign-again-mocks-john-fetterman-over-stroke-politics-are-dirty-but-have-we-sunk-to-a-n">publicly mocked Fetterman </a>on several occasions for refusing to debate him after the former Lt. governor of Pennsylvania suffered a stroke that affected his speech.
Then, the conflict intensified between Trump and Fetterman. At the time, <a href="https://www.benzinga.com/markets/cannabis/22/09/28749697/maga-rally-trump-calls-for-death-to-drug-dealers-says-fetterman-uses-hard-drugs-and-wears-dirty-" target="_blank" rel="noopener">Trump accused Fetterman</a> of supporting "taxpayer-funded drug dens and the complete decriminalization of illegal drugs, including heroin, cocaine, crystal meth, and ultra-lethal fentanyl, and by the way, he takes them himself." For the record, Fetterman does <a href="https://www.benzinga.com/markets/cannabis/23/11/35959706/fetterman-says-cannabis-legalization-is-inevitable-despite-some-republican-opposition">support the legalization</a> of cannabis.
<h2 class="wp-block-heading">Immigration And The Southern Border: Almost A Bipartisan Issue</h2>
Fetterman was the first Democrat to sponsor the Laken Riley Act, which <a href="https://www.benzinga.com/general/24/03/37625012/donald-trump-says-laken-riley-would-be-alive-today-under-his-administration-as-biden-apologizes-for">came up often</a> during Trump's 2024 presidential campaign. The legislation, named after a nursing student who was killed by an undocumented&nbsp;Venezuelan immigrant, would compel the federal government to detain noncitizens convicted or charged with burglary, larceny, theft or shoplifting.
As of Thursday, with a vote of 84-9 with 32 Democrats and one independent&nbsp;joining all 51 Republicans, <a href="https://www.nbcnews.com/politics/congress/senate-laken-riley-act-vote-illegal-immigration-rcna186775">reported</a> NBC News, the bill cleared the threshold to move on to the GOP-controlled Senate.
&#8220;We absolutely need to have a secure border, and I have always also been incredibly supportive and protective for Dreamers,&#8221; Fetterman <a href="https://www.washingtonexaminer.com/opinion/columnists/3280616/john-fetterman-laken-riley-act-common-sense/">told</a> the Washington Examiner on Tuesday, referring to young people who were born in the U.S. to undocumented parents and therefore may face deportation.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/01/42902618/canadian-official-claps-back-at-trumps-51st-state-comments-offers-to-buy-these-two-american-states">Canadian Official Claps Back At Trump&#8217;s 51st State Comments, Offers To Buy These Two American States</a></li>
</ul>
Photo of Fetterman by OogImages on Shutterstock

Cannabis

Government

Politics

John Fetterman First Democratic Lawmaker To Accept Trump Invitation To Mar-a-Lago Since 2024 Election

Iron Mountain (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRM#NYSE">IRM</a>) has outperformed the market over the past 5 years by 14.96% on an annualized basis producing an average annual return of 27.44%. Currently, Iron Mountain has a market capitalization of $29.99 billion. 
Buying $100 In IRM: If an investor had bought $100 of IRM stock 5 years ago, it would be worth $333.50 today based on a price of $102.20 for IRM at the time of writing.
<h3>Iron Mountain's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736518523_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Short Sellers

TMDX

Watching TransMedics Shares, Scorpion Capital Publishes Report On Co. With $0 PT

Wells Fargo analyst Mohit Bansal maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight and lowers the price target from $555 to $460.

VRTX

Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $460

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $1050 to $900.

REGN

Wells Fargo Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $900

WIIM

TLRY

Tilray Brands shares are trading lower after the company reported worse-than-expected Q2 revenue results.

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is seeing volatile trading on Friday, briefly regaining the $95,000 market before slumping below $94,000 on a hotter-than-expected j<a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42912480/us-economy-adds-256000-payrolls-in-december-as-tight-labor-market-tops-forecasts-dollar-treasury-yields-spike">obs market report</a>.
What Happened: The apex cryptocurrency is trading down 2% over the past 24 hours, having visited the $92,000 and $95,000 marks within this timeframe.
Prominent technical analyst DonAlt remains somewhat upbeat about its prospects, despite current volatility.
In his latest technical analysis podcast <a href="https://www.youtube.com/watch?v=x-W-JUZ9jLo">published</a> on Wednesday, DonAlt acknowledged that recent pullbacks have caused concern but stressed that Bitcoin's high timeframe charts remain strong. 
He suggests the reaction to recent dips might be overblown, stating, "Bitcoin still looks quite decent. I think $150,000 would already be significant this cycle."
He also underscored that the maturing market might not deliver the explosive gains seen in previous cycles, urging investors to temper expectations.
Regarding Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), DonAlt pointed to $2,900-$3,000 as a critical support level. 
He doesn't consider Ethereum "cooked" unless it breaks below this range. 
XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), meanwhile, stands out as a top performer. He praised its current chart, saying, "It's just a good-looking chart."
On the topic of FTX payouts, DonAlt suggested that the potential market impact is limited, as many large claim holders have already sold their stakes.
He also emphasized that the crypto market has matured, making sharp corrections less frequent but also reducing the likelihood of dramatic upward moves.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42881109/bitcoin-is-suffering-from-a-shift-in-macro-expectations-analyst-says-heres-what-that-means">Bitcoin Is Suffering From A Shift In Macro Expectations, Analyst Says: Here&#8217;s What That Means</a>
What's Next: Looking ahead, DonAlt predicts the current market cycle is nearing its conclusion, estimating it could wrap up in a few months. 
However, he remains hopeful for an "aggressive last leg" of growth before the cycle ends.
He cited former President Donald Trump's pro-crypto stance as a potential driver for market expansion, noting, "Trump is trying to pump this market, and I think it's still small enough for him to influence."
DonAlt urged caution, emphasizing the importance of managing risk and securing profits, as the market might not replicate previous cycles&#8217; meteoric gains.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42900509/social-media-sentiment-report-shows-only-one-out-of-bitcoin-xrp-dogecoin-is-bullish">Social Media Sentiment Report Shows Only One Out Of Bitcoin, XRP, Dogecoin Is Bullish</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

Bitcoin Fights To Regain $94,000: What Does Technical Analysis Say?

Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Equal-Weight and lowers the price target from $190 to $165.

BIIB

Wells Fargo Maintains Equal-Weight on Biogen, Lowers Price Target to $165

Penguin Solutions, Inc. - Ordinary Shares

PENG

Penguin Solutions shares are trading higher after the company reported better-than-expected Q1 financial results.

Roth MKM analyst Mike Niehuser maintains Vizsla Silver (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VZLA#AMEX">VZLA</a>) with a Buy and raises the price target from $3 to $3.25.

VZLA

Roth MKM Maintains Buy on Vizsla Silver, Raises Price Target to $3.25

Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Equal-Weight and lowers the price target from $335 to $280.

AMGN

Wells Fargo Maintains Equal-Weight on Amgen, Lowers Price Target to $280

PCRX

Pacira Biosciences shares are trading higher after the company reported a preliminary year-over-year increase in FY25 revenue.

RVSN

Rail Vision shares are trading higher after the company announced it received a purchase order for its MainLine product from one of the leading Central America freight operators.

Wells Fargo analyst Roger Read maintains Shell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) with a Overweight and lowers the price target from $87 to $86.

SHEL

Wells Fargo Maintains Overweight on Shell, Lowers Price Target to $86

Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA

Cannabix Technologies (TSE:BLO) has released an update. Cannabix Technologies Inc. is set to enhance workplace and public safety by partnering with...

Cannabix Technologies Innovates Workplace Safety

Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference

Cannabix Technologies (TSE:BLO) has released an update. Cannabix Technologies Inc. has enhanced its marijuana breathalyzer technology with new feat...

Cannabix Technologies Unveils Advanced Marijuana Breathalyzer

Cannabix Technologies (TSE:BLO) has released an update. Cannabix Technologies has received a positive certification for its Breath Logix autonomous...

Cannabix Technologies Gains Certification for Breathalyzer

Cannabix Technologies ( ($TSE:BLO) ) has provided an announcement. Cannabix Technologies has announced significant updates to its Cannabix Marijuan...

Cannabix Technologies Advances Marijuana Breathalyzer Technology

BLOZF

Press Releases

Cannabix Technologies and Omega Laboratories Inc. Enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology

Breathalyzer Innovations Meet Rising Demand as Cannabis Market Booms

Cannabix Technologies Annual General and Special Meeting Results

Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing

U.S. Cannabis Market Soars Amid Legal Reforms, But Safety Concerns Persist

New Breathalyzer Technology Could Revolutionize Cannabis DUI Detection

Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology – Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference

Comments

Cannabix Technologies

Cannabix Technologies (BLOZF) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル